Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 5 and last traded at GBX 5.44, with a volume of 679616 shares. The stock had previously closed at GBX 5.90.
Allergy Therapeutics Stock Up 9.9%
The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The stock has a 50 day simple moving average of GBX 7.27 and a 200 day simple moving average of GBX 9.56. The stock has a market cap of £378.69 million, a price-to-earnings ratio of -6.16, a PEG ratio of -30.70 and a beta of 0.87.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Recommended Stories
- Five stocks we like better than Allergy Therapeutics
- MarketBeat Week in Review – 07/27- 07/31
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
